# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
-Reuters
- Reuters
The FDA approval was based on positive results from the pediatric T2NOW Phase III trial. FARXIGA was previously approved in the...
- Reuters
- Reuters
AstraZeneca's supplemental New Drug Application (sNDA) for Tagrisso (osimertinib) has been accepted and granted Priority Re...
- Reuters
- Bloomberg
- Reuters